LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
CINCINNATI, Aug. 08, 2017 -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Board of Directors elected a new independent director, John M. Rice, Ph.D., effective August 8, 2017.
Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies. Since 2014, Mr. Rice has served as the Director of Life Sciences at CincyTech, a firm that provides advice and capital to entrepreneurs and helps research institutions commercialize technology through startups. He has served on the board of directors of several privately held healthcare companies.
John A. Kraeutler, Chairman and Chief Executive Officer, commented, “With the election of John to the Board of Directors of Meridian Bioscience we have added key strategic and scientific strengths to help guide our future growth. Our Nominating Committee has been working diligently for the last year to add specific skills to the Board. We are very pleased that John has agreed to join our team. I look forward to working with John and our existing directors as we build a strong future for Meridian Bioscience.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Contact: John A. Kraeutler Chairman, Chief Executive Officer Meridian Bioscience, Inc. Phone: 513.271.3700 Email: [email protected]
